Big Pharma Expands Investments in Cell Therapy
Updated: Apr 7, 2019
From Frost & Sullivan’s recent analysis, Growth Opportunities in the Global Cell Therapy Market, Forecast to 2025:
"Amendments in regulatory and reimbursement policies, as well as the implementation of conditional approval policies for RM, will further drive the market by expediting product launches.
"Additionally, improvements in cell culturing techniques alongside the use of different stem cells such as adipose-derived stem cells (ADSCs), mesenchymal stem cells (MSCs), and induced Pluripotent Stem Cells will strengthen the market with superior treatment options for non-oncological conditions such as neurological, musculoskeletal, and dermatological conditions."
Frost & Sullivan go on to state that “With the rising demand for cell therapies, the following growth opportunities have multiplied for vendors:
Wide-ranging therapeutic focus across both oncology and non-oncology conditions. With more than 959 ongoing regenerative medicine clinical trials, the market finds opportunity across both stem cell and non-stem cell based therapies.
Curative Combination Therapies which help to improve response rates among patients while reducing the duration of response. These therapies also find application in identifying the right patient as well as predicting the immune response in cancer patients.
Manufacturing Automation by means of implementation of IT solutions and single-use manufacturing techniques for optimizing small-volume, high-value manufacturing of novel cell therapies, thereby reducing the time to market drastically.
Emerging Business Models which help market players focus on academic and research collaborations alongside industry collaborations to support therapeutic and technological innovations.